The requirements for Mounjaro: what you actually need to qualify

Picture this: you've heard Mounjaro might help, but you're not sure if you tick the boxes

It is a common starting point. Someone mentions tirzepatide, you look it up, and the first thing you find is a BMI threshold. But the number on a scale is only the opening line of the eligibility story. The licensed criteria in the UK, as set out in the Mounjaro prescribing information, cover adults with a BMI of 30 or above, and adults with a BMI between 27 and 29.9 who have at least one weight-related comorbidity. Conditions that count include type 2 diabetes, raised blood pressure, dyslipidaemia (high cholesterol or triglycerides), and obstructive sleep apnoea, among others. If you have been living with one of those conditions, a BMI of 27 may be enough to meet the licensed threshold. UK clinical guidance also notes that these BMI thresholds are typically 2.5 kg/m² lower for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, reflecting differences in health risk at a given body weight. You can read the eligibility detail alongside the full clinical context on the Mounjaro overview page.

What a prescriber weighs up when they read your consultation

Meeting the BMI criterion opens the door. It does not walk you through it. A GPhC-registered prescriber reads your answers, your medical history and the results of your verification checks, this is what "same-day clinical review" means at a regulated pharmacy. They are looking at whether any contraindications apply: a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, a history of pancreatitis, or certain gastrointestinal conditions would all require careful discussion. Pregnancy, breastfeeding and actively trying to conceive are reasons Mounjaro is not recommended, and the treatment is not licensed for under-18s. The prescriber also considers your other medicines, oral contraceptives in particular interact with tirzepatide's effect on gastric emptying, and NHS guidance suggests adding a non-oral method of contraception for the first four weeks of treatment and for four weeks after each dose increase. None of this is there to catch you out. It is there because a prescription without that review is not a prescription, it is a risk. Our clinical team are clear on that point.

How NHS and private routes apply different layers of requirements

The licensed eligibility criteria are the baseline for any prescriber in the UK. On top of those, the NHS adds its own access criteria. NICE's appraisal of tirzepatide (TA1026) recommends it specifically for adults with a BMI of 35 or above plus at least one weight-related comorbidity, within a managed NHS pathway. Cohorts are being phased in gradually, from around June 2026, that has expanded to include people with a BMI of 35–39.9 alongside four or more qualifying conditions. NHS access also requires participation in a wraparound diet and activity support programme, and waiting lists exist in most areas. Private prescribing operates under the licensed criteria directly, not the NICE ones. That means a prescriber at a regulated private pharmacy can assess someone with a BMI of 30 who does not meet the NHS's comorbidity count, as long as the overall clinical picture supports it. It is worth understanding which set of criteria applies to your route before you assume you do or do not qualify. A question our prescribers field most weeks is from people who were turned down by one route and assumed the other would say the same thing, that is not always true.

Age, timing and a few practical notes before you start

Mounjaro is licensed for adults, which means 18 and over. Age at the upper end is not itself a barrier, but a prescriber will factor in any age-related health considerations as part of the full review. There is no upper age limit in the licensed criteria. Timing matters too: if you are switching from another GLP-1 treatment, or asking about a dose increase, a prescriber needs evidence of your current dose and recent weight before making that decision. For those transferring from another provider, that means bringing documentation. If you want to understand the different names Mounjaro goes by across markets and prescriptions, that context can also help when you are comparing providers or transferring records. If you are curious about how Mounjaro sits alongside other treatments, the comparison with newer agents like retatrutide is worth a read for context. One practical note on the treatment itself: once you are prescribed and your pen arrives, it needs to go straight into the fridge, the KwikPen is stored at 2–8°C, so the fridge door is the right place, not the kitchen counter. The NHS tirzepatide page has storage detail alongside a plain-language summary of how the medicine works. If cost is part of what you are thinking through, the payment plan page covers what is included in a private prescription price and what to watch for when comparing providers. People also commonly ask about which supplements work well alongside Mounjaro, and that page covers what the evidence currently supports. Those who finish a course of treatment and wonder what comes next can find guidance on what to consider as a replacement for Mounjaro when the time comes. When you feel ready to find out whether you meet the requirements, a free consultation with our prescribers is the place to start.